Neurocrine Biosciences (NBIX) Cash from Financing Activities (2010 - 2026)

Neurocrine Biosciences has reported Cash from Financing Activities for 17 years, with the latest figure at $63.4 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at $63.4 million, up 2021.21% year-over-year; the trailing twelve-month figure through Jun 2026 was $60.2 million (up 115.64% YoY), and the FY2025 annual result was -$38.3 million, up 92.13% from the prior year.
• Cash from Financing Activities climbed to $63.4 million in Q2 2026, from -$86.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $69.9 million in Q1 2024 and troughed at -$293.0 million in Q2 2024.
• A 5-year average of -$39.8 million and a median of $9.8 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2024, when Cash from Financing Activities plunged 10203.45%; it then surged 2021.21% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $24.6 million in 2022, then soared by 43.9% to $35.4 million in 2023, then slumped by 919.21% to -$290.0 million in 2024, then surged by 112.86% to $37.3 million in 2025, then surged by 69.97% to $63.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $63.4 million in Q2 2026, -$86.1 million in Q1 2026, and $37.3 million in Q4 2025.